Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy (HOMER)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2016 by Novartis
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Novartis
ClinicalTrials.gov Identifier:
NCT01200589
First received: September 10, 2010
Last updated: March 22, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2020
  Estimated Primary Completion Date: September 2020 (Final data collection date for primary outcome measure)